TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Apnimed Stock

Apnimed Stock

apnimed.comHealthcareFounded: 2017Funding to Date: $208.02MM

Apnimed, founded in 2017, is a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, MA, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Buy or sell Apnimed stockLearn more about Apnimed IPO
Register for Details

For more details on financing and valuation for Apnimed, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Apnimed.

Register Today

Apnimed investors also invested in these private companies

Tao Capital Partners
Morningside Group
Alpha Wave Global
NexPoint
Sectoral Asset Management
Seligman Technology Group

Team

Management Team

Dennis Molnar
Chief Operating Officer
Luigi Montemurro MD
Co-Founder & Chief Scientific Officer
Barry Wohl
Chief Business Officer
Rob Rode
Chief Commercial Officer
Andrew Wellman MD
Co-Founder & Advisor
Ron Farkas Ph.D
Chief Medical Officer
Lawrence Miller MD
Founder & Chief Executive Officer
Michael Rogers
Chief Financial Officer

Board Members

Chris Dimitropoulos
Alpha Wave Global
Isaac Cheng MD
Morningside Group
Stefan Larson Ph.D
Sectoral Asset Management

Other companies like Apnimed in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Precision Neuroscience
Sector
Healthcare
 
 

News

BUSINESSWIRE 01/03/2023
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced today that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.

Trending Companies

Frequently Asked Questions